Pyxis Oncology (PYXS) Free Cash Flow (2020 - 2025)
Pyxis Oncology (PYXS) posted quarterly Free Cash Flow of -$10.4 million for Q4 2025, up 45.95% year-over-year from -$7.1 million in Q4 2024, and up 21.47% quarter-over-quarter from -$13.3 million in Q3 2025.
Pyxis Oncology (PYXS) Free Cash Flow (2020 - 2025) Analysis & Trends
Pyxis Oncology (PYXS) has reported Free Cash Flow for 6 consecutive years, with -$10.4 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Free Cash Flow rose 45.95% year-over-year to -$10.4 million; the TTM figure through Dec 2025 stood at -$63.5 million (down 9.66% YoY), while the FY2025 annual figure was -$63.5 million, down 9.67% from the prior year.
- Free Cash Flow climbed to -$10.4 million in Q4 2025 per PYXS's latest filing, from -$13.3 million in the prior quarter.
- Across five years, Free Cash Flow topped out at $2.5 million in Q2 2021 and bottomed at -$29.1 million in Q1 2023.
- Historically, Free Cash Flow has averaged -$16.2 million across 5 years, with a median of -$17.5 million in 2023.
- Annual changes were most pronounced in 2022 — Free Cash Flow plunged 1049.3% — and 2024, when it jumped 80.52%.
- Pyxis Oncology's Free Cash Flow stood at -$12.2 million in 2021, then tumbled by 84.29% to -$22.4 million in 2022, then soared by 60.92% to -$8.8 million in 2023, then tumbled by 120.08% to -$19.3 million in 2024, then soared by 45.95% to -$10.4 million in 2025.
- Business Quant data shows PYXS's Free Cash Flow at -$10.4 million in Q4 2025, -$13.3 million in Q3 2025, and -$17.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Pyxis Oncology | 198.37 Mn | 165.38 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -10.43 Mn |
| Dec 31, 2025 | -10.43 Mn |
| Sep 30, 2025 | -13.28 Mn |
| Sep 30, 2025 | -13.28 Mn |
| Jun 30, 2025 | -17.26 Mn |
| Jun 30, 2025 | -17.26 Mn |
| Mar 31, 2025 | -22.54 Mn |
| Mar 31, 2025 | -22.54 Mn |
| Dec 31, 2024 | -19.29 Mn |
| Dec 31, 2024 | -19.29 Mn |
| Sep 30, 2024 | -14.67 Mn |
| Sep 30, 2024 | -14.67 Mn |
| Jun 30, 2024 | -3.01 Mn |
| Jun 30, 2024 | -3.01 Mn |
| Mar 31, 2024 | -20.95 Mn |
| Mar 31, 2024 | -20.95 Mn |
| Dec 31, 2023 | -8.77 Mn |
| Dec 31, 2023 | -8.77 Mn |
| Sep 30, 2023 | -17.64 Mn |
| Sep 30, 2023 | -17.64 Mn |